Alveolar OsteitisNCT07139340
Does the Use of HA Gel Following Third Molar Extraction Decrease the Incidence of Alveolar Osteitis?
A study testing HA gel in people with Alveolar Osteitis, run by Delta University for Science and Technology at 1 site in Egypt.
Trial summary
The study aimed to investigate the effectiveness of Hyaluronic Acid gel on decreasing the incidence of alveolar osteitis after mandibular third molar extraction. Read more about this study
- Who is it for?
- Ages 18 to 33 yearsHealthy volunteers can take part
- Conditions the study is for
- Alveolar Osteitis
- What is being tested?
- HA gel
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Aug 2021to 1 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 33 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy patients (ASA=1)
- Patients need extraction of mandibular third molar
- Patients can attend recalls
Who cannot join
- Smoking patients
- Patients taking oral contraceptive pills
- Bad oral hygiene
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Delta university for science and technology
Gamasa, Dakahlia Governorate, 7731168
About this study
The study aimed to investigate the effectiveness of Hyaluronic Acid gel on decreasing the incidence of alveolar osteitis after mandibular third molar extraction.
- Conditions
- Alveolar Osteitis
- Being tested
- HA gel
- Medical subject headings
- Dry Socket
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HA gelOther
Also called Hyaluronic Acid gel
Hyaluronic Acid gel 0.8% 1 mL
| Study group | Role | What they receive |
|---|---|---|
| Study group (HA gel) | Active comparator | HA gel was placed intrasocket after extraction Receives: Other: HA gel |
| Control group (No HA gel) | No intervention | Nothing was placed intrasocket after extraction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurence of Alveolar Osteitis (AO)
Presence of empty extraction socket without healing clot indicates AO (measured by clinical inspection; Presence of AO=1, Absence of AO=0)
Measured: 7 postoperative days
Secondary outcomes (1)
Postoperative pain
Presence of postoperative pain (measured by Visual Analogue Scale (VAS) from 0 (least pain) to 10 (worst pain))
Measured: 7 postoperative days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2025
- Study start30 Aug 2021
- Primary completion1 Aug 2025
- Study completion1 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alveolar OsteitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Control group (No HA gel), and study group (HA gel)
- Masking
- None (open label)
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Delta University for Science and Technology
- Sponsor type
- University, hospital or other
- Collaborators
- Mansoura University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07139340
- Sponsor's protocol ID
- A300816
- Status last verified
- Aug 2021
- First submitted
- 17 Aug 2025
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does the Use of HA Gel Following Third Molar Extraction Decrease the Incidence of Alveolar Osteitis?
- ClinicalTrials.gov ID
- NCT07139340
- Acronym / sponsor ID
- A300816
- Conditions
- Alveolar Osteitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Delta University for Science and TechnologyUniversity, hospital or other
- Collaborators
- Mansoura University
- Study start
- 30 Aug 2021 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Dec 2025 (actual)
- First posted
- 24 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aimed to investigate the effectiveness of Hyaluronic Acid gel on decreasing the incidence of alveolar osteitis after mandibular third molar extraction.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Control group (No HA gel), and study group (HA gel)
| Arm | Type | Receives |
|---|---|---|
| Study group (HA gel) | Active comparator | Other: HA gelHA gel was placed intrasocket after extraction |
| Control group (No HA gel) | No intervention | –Nothing was placed intrasocket after extraction |
Who may qualify
- Ages
- 18 to 33 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy patients (ASA=1)
- Patients need extraction of mandibular third molar
- Patients can attend recalls
Key exclusion criteria (3 listed)
- Smoking patients
- Patients taking oral contraceptive pills
- Bad oral hygiene
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HA gelAlso: Hyaluronic Acid gelHyaluronic Acid gel 0.8% 1 mL | Other | Study group (HA gel) |
Primary outcome
Occurence of Alveolar Osteitis (AO)
Time frame: 7 postoperative days
Presence of empty extraction socket without healing clot indicates AO (measured by clinical inspection; Presence of AO=1, Absence of AO=0)
1 secondary outcome
Postoperative pain
Time frame: 7 postoperative days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Alveolar Osteitis
Recruiting
Effect of Curcumin Topical Spray on Wound Healing After Tooth Extraction
Wound Healing, Alveolitis of Jaw
Not yet recruiting
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis
Alveolar Osteitis
Not yet recruiting
Effectiveness of Telephonic and Digital Postoperative Follow-up Communication Strategies on Patient Compliance, Clinical Recovery, and Quality of Life After Dental Extraction
Tooth Extraction, Postoperative Care
RecruitingObservational study
PERIodontal Disease, Microbiota and Miscarriage
Miscarriage, Parodontitis
Active, not recruitingEarly Phase 1
Ozone Oil-based Gel and CHX Gel After Lower Third Molar Removal
Pain, Dry Socket
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HA gel in people with Alveolar Osteitis, run by Delta University for Science and Technology at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Occurence of Alveolar Osteitis (AO) (time frame: 7 postoperative days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.